Nicholas Develops Drug Leads From Antarctica (India)
This article was originally published in PharmAsia News
Executive Summary
India-based Nicholas Piramal India (NPI) is developing pharmaceuticals from the flora and fauna of Antarctica. NPI may be the first company worldwide to develop a full-scale product from there. NPI soon plans to apply for patents for two antibiotics still being designed from live Antarctic microbes; these antibiotics may be useful for treating cancer. "The live microbes in Antarctica exist in less than minus 50 degree Celsius, which prompted us to think of collecting rare species of microbes with potential drug leads," says NPI scientist Swati Piramal. NPI traveled to the continent in December 2005, and to date India's government has led 26 expeditions there. In 2006 researchers with India's Central Council for Research in Ayurveda and Siddha developed two herbal supplements to boost energy from Antarctica, Antarctica Tea and Antarctica Laddoo. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.